828-02-4

Basic information

• Product Name: D-Alanine, N-phenyl-
• CAS NO: 828-02-4
• Molecular Formula: C9H11NO2
• Molecular Weight: 165.192
• Mol File: 828-02-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: D-Alanine, N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: D-Alanine, N-phenyl-(828-02-4)
• EPA Substance Registry System: D-Alanine, N-phenyl-(828-02-4)

Safety Data

• Hazardous Substances Data: 828-02-4(Hazardous Substances Data)

Upstream product

• 709-80-8 methyl N-(2, 6-dimethylphenyl)alaninate 
• 56-41-7 L-alanin 
• 108-90-7 chlorobenzene 
• 591-50-4 iodobenzene 
• 338-69-2 D-Alanine 
• 62-53-3 aniline 
• 88912-03-2 ethyl 2-phenylaminopropionate 
• 15727-49-8 N-Phenylalanin 

Downstream Products

• 13514-15-3 (2Ξ,4R)-2,4-dimethyl-2,3-diphenyl-[1,3,2]oxazasilolidine-5-one 
• 42990-55-6 (S)-(alpha)-bromobenzenepropanoic acid 
• 1270015-25-2 (R)-N-((R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-2-(phenylamino)propanamide 

Relevant articles and documents

Development of a scalable process for a key intermediate of (R)-metalaxyl by enzymatic kinetic resolution

A scale-up study was carried out for the enzyme-catalyzed kinetic resolution of 2-methoxyethyl N-(2,6)-dimethylphenyl)-alaninate rac-3 for the preparation of (R)-metalaxyl at 20-L scale. Immobilization of lipase PS on a polymeric support enabled the reuse of the enzyme. The unreacted enantiomer was racemized by means of acid/aldehyde catalyzed Schiff base intermediate formation. The combination of lipase PS-catalyzed hydrolytic kinetic resolution and racemization of the remaining ester gave a satisfactory reaction yield (> 80%) and high enantiomeric excess (96% ee) for one recycle.

HETEROARYL BTK INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

NOVEL COMPOUNDS

This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.